mTeSR™1
cGMP, feeder-free maintenance medium for human ES and iPS cells
-
mTeSR™1 -
Label for mTeSR™1 -
Label for mTeSR™1
More Views
Overview
mTeSR™1, now manufactured under cGMP, is the most widely published feeder-free cell culture medium for human embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells), with established protocols for applications ranging from derivation to differentiation. It has been used to successfully maintain thousands of ES and iPS cell lines in over 50 countries, and has supported top pluripotent stem cell publications and researchers. mTeSR™1 is a highly specialized, serum-free and complete cell culture medium. With pre-screened raw materials that ensure batch-to-batch consistency and robust feeder-free protocols for ES and iPS cell culture, mTeSR™1 provides more consistent cultures with homogeneous, undifferentiated phenotypes.
mTeSR™1 is manufactured under a cGMP quality management system compliant to 21 CFR 820, ensuring the highest quality and consistency for reproducible results.
To request a Letter of Authorization (LOA) for mTeSR’s Drug Master File, click here.
mTeSR™1 is manufactured under a cGMP quality management system compliant to 21 CFR 820, ensuring the highest quality and consistency for reproducible results.
To request a Letter of Authorization (LOA) for mTeSR’s Drug Master File, click here.
Components:
- mTeSR™1 Complete Kit (Catalog #85850)
- mTeSR™1 Basal Medium, 400 mL
- mTeSR™1 5X Supplement, 100 mL
- mTeSR™1 Complete Kit, 1 L (Catalog #85857)
- mTeSR™1 Basal Medium, 800 mL
- mTeSR™1 5X Supplement, 100 mL, 2 Bottles
- mTeSR™1 Complete Kit, 10 Pack (Catalog #85870)
- mTeSR™1 Basal Medium, 400 mL, 10 Bottles
- mTeSR™1 5X Supplement, 100 mL, 10 Bottles
- mTeSR™1 Complete Kit, 25 Pack (Catalog #85875)
- mTeSR™1 Basal Medium, 400 mL, 25 Bottles
- mTeSR™1 5X Supplement, 100 mL, 25 Bottles
Subtype:
Specialized Media
Cell Type:
Pluripotent Stem Cells
Species:
Human
Application:
Cell Culture; Expansion; Maintenance
Brand:
TeSR
Area of Interest:
Stem Cell Biology
Formulation:
Serum-Free
Related Products
-
Defined supplement for single-cell cloning of human ES and iPS cells -
Defined, xeno-free matrix that supports the growth and differentiation of human pluripotent stem cells under serum-free, feeder-free conditions -
Enzyme-free human ES and iPS cell selection and passaging reagent
Scientific Resources
Product Documentation
Document Type
Product Name
Catalog #
Lot #
Language
Educational Materials
(35)
Load More Educational Materials
Product Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area
Workflow Stages for
Workflow Stages
Data and Publications
Data
Figure 1. Normal hES and hiPS Cell Morphology is Observed in cGMP mTeSR™1 Cultures
Undifferentiated (A) H1 human embryonic stem (hES) and (B) WLS-1C human induced pluripotent stem (hiPS) cells cultured on Corning® Matrigel® Matrix in cGMP mTeSR™1 retain the prominent nucleoli and high nuclear-to-cytoplasmic ratio characteristic of this cell type after 10 passages. Densely packed cells and multi-layering are prominent when cells are ready to be passaged.
Figure 2. High Expansion Rates are Observed in cGMP mTeSR™1 Cultures
Graph shows the average fold expansion per passage +/- SEM obtained for hES (H1 and H9) and hiPS (WLS-1C) cells cultured in cGMP mTeSR™1 (red) or non-cGMP mTeSR™1 (gray) on Corning® Matrigel® Matrix over 10 passages. Expansion was determined by enumerating the cell aggregates obtained at harvest and dividing by the number of cell aggregates seeded. Note that this data is representative of cultures passaged after 6-7 days in culture, lower expansion should be expected if using shorter culture times.
Figure 3. Cells Cultured in cGMP mTeSR™1 Medium Express Undifferentiated Cell Markers
Histogram analysis for hES (H1 and H9) and hiPS (WLS-1C) cells characterized using FACS for undifferentiated cell markers, OCT4 (OCT3) (Catalog #60093) and TRA-1-60 (Catalog #60064), after 8 - 10 passages in cGMP mTeSR™1 (filled = sample, blank = isotype control).
Figure 4. hPSCs Maintained in cGMP mTeSR™1 Display a Normal Karyotype
Karyograms of (A) H1 hES and (B) WLS-1C hiPS cells cultured in cGMP mTeSR™1 for 11 passages shows that a normal karyotype is retained.
Publications
(1565)
Human immunology 2019 jul
Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch.
Abstract
Abstract
Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1{\%} to 5.3{\%}. Patients with native diseases considered 'immunological' (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3{\%}) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors.
eLife 2019
Human perivascular stem cell-derived extracellular vesicles mediate bone repair.
Abstract
Abstract
The vascular wall is a source of progenitor cells that are able to induce skeletal repair, primarily by paracrine mechanisms. Here, the paracrine role of extracellular vesicles (EVs) in bone healing was investigated. First, purified human perivascular stem cells (PSCs) were observed to induce mitogenic, pro-migratory, and pro-osteogenic effects on osteoprogenitor cells while in non-contact co-culture via elaboration of EVs. PSC-derived EVs shared mitogenic, pro-migratory, and pro-osteogenic properties of their parent cell. PSC-EV effects were dependent on surface-associated tetraspanins, as demonstrated by EV trypsinization, or neutralizing antibodies for CD9 or CD81. Moreover, shRNA knockdown in recipient cells demonstrated requirement for the CD9/CD81 binding partners IGSF8 and PTGFRN for EV bioactivity. Finally, PSC-EVs stimulated bone repair, and did so via stimulation of skeletal cell proliferation, migration, and osteodifferentiation. In sum, PSC-EVs mediate the same tissue repair effects of perivascular stem cells, and represent an 'off-the-shelf' alternative for bone tissue regeneration.
Nature methods 2018 SEP
Rapid and efficient induction of functional astrocytes from human pluripotent stem cells.
Abstract
Abstract
The derivation of astrocytes from human pluripotent stem cells is currently slow and inefficient. We demonstrate that overexpression of the transcription factors SOX9 and NFIB in human pluripotent stem cells rapidly and efficiently yields homogeneous populations of induced astrocytes. In our study these cells exhibited molecular and functional properties resembling those of adult human astrocytes and were deemed suitable for disease modeling. Our method provides new possibilities for the study of human astrocytes in health and disease.
Stem cell reports 2018 MAY
Inflammatory Responses and Barrier Function of Endothelial Cells Derived from Human Induced Pluripotent Stem Cells.
Abstract
Abstract
Several studies have reported endothelial cell (EC) derivation from human induced pluripotent stem cells (hiPSCs). However, few have explored their functional properties in depth with respect to line-to-line and batch-to-batch variability and how they relate to primary ECs. We therefore carried out accurate characterization of hiPSC-derived ECs (hiPSC-ECs) from multiple (non-integrating) hiPSC lines and compared them with primary ECs in various functional assays, which included barrier function using real-time impedance spectroscopy with an integrated assay of electric wound healing, endothelia-leukocyte interaction under physiological flow to mimic inflammation and angiogenic responses in in vitro and in vivo assays. Overall, we found many similarities but also some important differences between hiPSC-derived and primary ECs. Assessment of vasculogenic responses in vivo showed little difference between primary ECs and hiPSC-ECs with regard to functional blood vessel formation, which may be important in future regenerative medicine applications requiring vascularization.
Journal of molecular and cellular cardiology 2018 MAY
Afterload promotes maturation of human induced pluripotent stem cell derived cardiomyocytes in engineered heart tissues.
Abstract
Abstract
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) grown in engineered heart tissue (EHT) can be used for drug screening, disease modeling, and heart repair. However, the immaturity of hiPSC-CMs currently limits their use. Because mechanical loading increases during development and facilitates cardiac maturation, we hypothesized that afterload would promote maturation of EHTs. To test this we developed a system in which EHTs are suspended between a rigid post and a flexible one, whose resistance to contraction can be modulated by applying braces of varying length. These braces allow us to adjust afterload conditions over two orders of magnitude by increasing the flexible post resistance from 0.09 up to 9.2 mu$N/mu$m. After three weeks in culture, optical tracking of post deflections revealed that auxotonic twitch forces increased in correlation with the degree of afterload, whereas twitch velocities decreased with afterload. Consequently, the power and work of the EHTs were maximal under intermediate afterloads. When studied isometrically, the inotropy of EHTs increased with afterload up to an intermediate resistance (0.45 mu$N/mu$m) and then plateaued. Applied afterload increased sarcomere length, cardiomyocyte area and elongation, which are hallmarks of maturation. Furthermore, progressively increasing the level of afterload led to improved calcium handling, increased expression of several key markers of cardiac maturation, including a shift from fetal to adult ventricular myosin heavy chain isoforms. However, at the highest afterload condition, markers of pathological hypertrophy and fibrosis were also upregulated, although the bulk tissue stiffness remained the same for all levels of applied afterload tested. Together, our results indicate that application of moderate afterloads can substantially improve the maturation of hiPSC-CMs in EHTs, while high afterload conditions may mimic certain aspects of human cardiac pathology resulting from elevated mechanical overload.
This product was developed under license to intellectual property owned by WiCell™ Research Institute (patent pending). This product is sold for research use only (whether the buyer is an academic or for-profit entity) under a non-transferable, limited-use license. Purchase of this product does not include the right to sell, use or otherwise transfer this product for commercial purposes (i.e., any activity undertaken for consideration, such as use of this product for manufacturing, or resale of this product or any materials made using this product, or use of this product or any materials made using this product to provide services) or clinical use (i.e., administration of this product or any material using this product to humans) or the right to implant any material made using this product into an animal by, or in collaboration with, a for-profit entity, for purposes other than basic pre-clinical research applications (including without limitation teratoma assays) to validate the function of the cells. Purchasers wishing to use the product for purposes other than research use should contact Asterias Biotherapeutics, Inc. legal department at (650) 433-2900 or legal@asteriasbio.com. Purchasers who do not agree to the terms and conditions set forth above should return the product in acceptable conditions to the seller for a refund.